Home > Resources > Whitepapers > Accelerating Antibody Development with Automated Octet Assays

Accelerating Antibody Development with Automated Octet Assays

March 11, 2019

Drug development and production are challenging, however, high throughput characterization systems can greatly accelerate discovery programs. Using a proprietary discovery and development platform technology, Avitide enables its partners to rapidly advance candidate molecules to the clinic and achieve faster and more predictable bioprocess development timelines.

Spotlight

HealthCare Partners, A DaVita Medical Group

HealthCare Partners, a DaVita Medical Group is the country's largest operator of medical groups and physician networks, provides integrated care management as an operating division of DaVita, focusing on delivering outstanding healthcare across a broad range of services. HealthCare Partners works with its patients to help them live life to the fullest and strives to lead the transformation of the national healthcare delivery system to ensure quality, accessible and affordable care for all.

OTHER WHITEPAPERS

Overcoming Pharma’s Launch Performance Problem

whitePaper | March 24, 2023

The prescription medicine market recovered from the wild swings of the early pandemic with renewed volume growth, driven by generics. COVID-19 vaccines and treatments have created a substantial market.

Read More

Multi-channel clinical trial recruitment technology checklist

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

Read More

Deal-Making Roundup

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

Read More

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

Read More

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of any company. For those in pharmaceutical contract research, development, or manufacturing.

Read More

Overcoming technical challenges in cell-based high throughput screens

whitePaper | November 11, 2022

Tremendous technological advancements in automated biotechnology and combinatorial chemistry have led to the widespread implementation of high throughput screening (HTS) for drug discovery since the early 1990s.

Read More

Overcoming Pharma’s Launch Performance Problem

whitePaper | March 24, 2023

The prescription medicine market recovered from the wild swings of the early pandemic with renewed volume growth, driven by generics. COVID-19 vaccines and treatments have created a substantial market.

Read More

Multi-channel clinical trial recruitment technology checklist

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

Read More

Deal-Making Roundup

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

Read More

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

Read More

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of
any company. For those in pharmaceutical contract research, development, or manufacturing.

Read More

Overcoming technical challenges in cell-based high throughput screens

whitePaper | November 11, 2022

Tremendous technological advancements in automated biotechnology and combinatorial chemistry have led to the widespread implementation of high throughput screening (HTS) for drug discovery since the early 1990s.

Read More

More Whitepapers

Spotlight

HealthCare Partners, A DaVita Medical Group

HealthCare Partners, a DaVita Medical Group is the country's largest operator of medical groups and physician networks, provides integrated care management as an operating division of DaVita, focusing on delivering outstanding healthcare across a broad range of services. HealthCare Partners works with its patients to help them live life to the fullest and strives to lead the transformation of the national healthcare delivery system to ensure quality, accessible and affordable care for all.

Events

National Medtech & Biotech Summit 2024

Conference

National Medtech & Biotech Summit 2024

Conference